Indevus Receives Approvable Letter from FDA for...(ird parties for supplies particularly fo...)

Date:6/30/2008

ird parties for supplies, particularly for histrelin, manufacturing, marketing, and clinical trials; risks associated with being a manufacturer of some of our products; risks associated with contractual agreements, particularly for the manufacture and co-promotion of SANCTURA and SANCTURA XR and the manufacture of NEBIDO, VANTAS, SUPPRELIN LA and VALSTAR; reliance on intellectual property and having limited patents and proprietary rights; dependence on market exclusivity, changes in reimbursement policies and/or rates for SANCTURA, SANCTURA XR, VANTAS, SUPPRELIN LA, DELATESTRYL and any future products; acceptance by the healthcare community of our approved products and product candidates; uncertainties relating to clinical trials, regulatory approval and commercialization of our products, particularly SANCTURA XR, NEBIDO, and VALSTAR; product liability and insurance uncertainties; risks relating to the Redux-related litigation; need for additional funds and corporate partners, including for the development of our products; history of operating losses and expectation of future losses; uncertainties relating to controls over financial reporting; difficulties in managing our growth; valuation of our Common Stock; risks related to repayment of debts; risks related to increased leverage; general worldwide economic conditions and related uncertainties; and other risks. Indevus undertakes no obligation to publicly update any forward- looking statement, whether as a result of new information, future events or otherwise.

Contact:

For Indevus

Michael W. Rogers Brooke D. Wagner

Executive Vice President and CFO VP, Corporate Communications

(781) 861-8444 (781) 402-3410

'/>"/>

SOURCE Indevus Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related biology technology :

1. Indevus Announces Management Changes
2. Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences
3. 125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative
4. Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference
5. Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R)
6. Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM)
7. Indevus Pharmaceuticals Announces Retirement of David B. Sharrock From Its Board of Directors
8. Indevus Announces Allergan as New Partner for SANCTURA Brand
9. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
10. Alfacell Receives NASDAQ Non-Compliance Notification
11. Albany College of Pharmacy Researcher Receives $368,445 Grant from the National Institutes of Health